This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Kinetic Modeling, Test-Retest, and Dosimetry of 123I-MNI-420 in Humans
- MRI-Guided Region-of-Interest Delineation Is Comparable to Manual Delineation in Dopamine Transporter SPECT Quantification in Patients: A Reproducibility Study
- The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-{beta}-CIT SPECT for Diagnosis of Dementia with Lewy Bodies
- Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1--Pseudoequilibrium Interval and Quantification Methods
- SPECT of Serotonin Transporters Using 123I-ADAM: Optimal Imaging Time After Bolus Injection and Long-Term Test-Retest in Healthy Volunteers
- Clinical Testing of an Optimized Software Solution for an Automated, Observer-Independent Evaluation of Dopamine Transporter SPECT Studies
- Increased Dopamine Transporter Availability Associated with the 9-Repeat Allele of the SLC6A3 Gene
- Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease
- Initial Human PET Imaging Studies with the Dopamine Transporter Ligand 18F-FECNT
- [123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson's disease progression